Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 10/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12915095 | 0.88 | MAPT (0.40) | CD38MAPTLRRK2DGAT1 | |
| SCHEMBL952876 | 0.86 | GRM5 (0.37) | GRM5MAPTCNR1CNR2ROCK1 | |
| SCHEMBL27655692 | 0.85 | DYRK1A (0.43) | MAPTDGAT1 | |
| SCHEMBL954077 | 0.84 | NPC1 (0.39) | GRM5MAPT | |
| SCHEMBL951815 | 0.84 | GRM5 (0.39) | GRM5MAPTCNR1CNR2DGAT1 | |
| SCHEMBL952406 | 0.84 | IKBKE (0.43) | GRM5MAPTABL1CPT1ACPT1B | |
| SCHEMBL954359 | 0.82 | GRM5 (0.36) | GRM5MAPTCNR1CNR2ROCK1 | |
| SCHEMBL954050 | 0.82 | GRM5 (0.37) | GRM5MAPTCNR1CNR2ABL1 | |
| SCHEMBL951128 | 0.82 | ABL1 (0.42) | GRM5MAPTABL1ROCK1 | |
| SCHEMBL953701 | 0.80 | PIK3C3 (0.41) | GRM5MAPTCPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| US-7842711-B2 | Indazolecarboxamide derivatives for the treatment and prevention of malaria | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| CN-1933834-A | Use of indazolecarboxamide derivatives for the preparation of a medicament for the treatment and prevention of malaria | SANOFI AVENTIS (FR) | 2007-03-21 | — | — | CN | disclosed |
| EP-1727544-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | Sanofi-Aventis (FR) | 2006-12-06 | — | — | EP | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| WO-2005099703-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | SANOFI-AVENTIS (FR) | 2005-10-27 | — | — | WO | disclosed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | GRM5 2216/4885CD38 568/4885MAPT 1165/4885 |
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | GRM5 2216/4885CD38 568/4885MAPT 1165/4885 |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | GRM5 3651/4885CD38 1218/4885MAPT 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.